broad_id
string | depmap_id
string | ccle_name
string | screen_id
string | upper_limit
int64 | lower_limit
float64 | slope
float64 | r2
float64 | auc
float64 | ec50
float64 | ic50
float64 | name
string | moa
string | target
string | disease.area
string | indication
string | smiles
string | phase
string | passed_str_profiling
bool | row_name
string |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BRD-K63712959-001-01-8 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 1.257534 | 0.149142 | 0.044989 | 1 | 0.496719 | null | temoporfin | radical formation stimulant | null | oncology | head and neck squamous cell carcinoma (HNSCC) | Oc1cccc(c1)-c1c2CCc(n2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc(n2)c(-c2cccc(O)c2)c2ccc1[nH]2 | Launched | true | ACH-000913 |
BRD-K64881305-001-03-7 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.245385 | 1.868416 | 0.717364 | 0.522519 | 0.021522 | 0.030885 | ispinesib | kinesin inhibitor | KIF11 | null | null | CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1 | Phase 2 | true | ACH-000913 |
BRD-K66175015-001-12-4 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.157668 | 6.178611 | 0.548777 | 0.913546 | 3.694608 | 3.928165 | afatinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | oncology | non-small cell lung cancer (NSCLC) | CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1 | Launched | true | ACH-000913 |
BRD-K67844266-003-01-9 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.474679 | 1.054383 | 0.368209 | 0.730229 | 0.06838 | 1.157699 | pevonedistat | nedd activating enzyme inhibitor | NAE1, UBA3 | null | null | NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12 | Phase 2 | true | ACH-000913 |
BRD-K69001009-001-02-8 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.682089 | -0.01968 | -0.012023 | 0.838707 | 0.348647 | null | golvatinib | VEGFR inhibitor | KDR, MET | null | null | CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1 | Phase 2 | true | ACH-000913 |
BRD-K69694239-001-02-2 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.438444 | 3.456817 | 0.646831 | 0.810888 | 0.380759 | 0.697931 | bardoxolone-methyl | nuclear factor erythroid derived, like (NRF2) activator | PPARG, STAT3 | null | null | COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 | Phase 3 | true | ACH-000913 |
BRD-K69776681-001-03-8 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.810185 | -0.260034 | -0.044187 | 0.918352 | 0.023048 | null | volasertib | PLK inhibitor | PLK1 | null | null | CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O | Phase 3 | true | ACH-000913 |
BRD-K70301465-001-05-9 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.616765 | 11.212251 | 0.242006 | 0.808439 | 0.078214 | null | ibrutinib | Bruton's tyrosine kinase (BTK) inhibitor | BLK, BMX, BTK | hematologic malignancy | chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM) | Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C | Launched | true | ACH-000913 |
BRD-K70401845-001-15-7 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.966952 | 2.080954 | 0.024457 | 0.987314 | 0.241095 | null | erlotinib | EGFR inhibitor | EGFR, NR1I2 | oncology | non-small cell lung cancer (NSCLC), pancreatic cancer | COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC | Launched | true | ACH-000913 |
BRD-K73838513-003-05-5 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.92761 | 0.532464 | 0.00432 | 0.959126 | 0.037562 | null | cinacalcet | calcium channel activator | CASR | endocrinology, nephrology, oncology | hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia | C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12 | Launched | true | ACH-000913 |
BRD-K74514084-003-09-2 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 1.256237 | -1.918557 | 0.260835 | 1 | 1.064143 | null | pazopanib | KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3 | oncology | renal cell carcinoma (RCC), soft tissue sarcoma (STS) | CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1 | Launched | true | ACH-000913 |
BRD-K75009076-001-02-1 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.342853 | 4.244451 | 0.40096 | 0.815009 | 0.650943 | 0.855011 | SCH-900776 | CHK inhibitor | CDK2, CHEK1 | null | null | Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1 | Phase 2 | true | ACH-000913 |
BRD-K76239644-001-02-6 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.126163 | 0.828389 | 0.406574 | 0.786655 | 1.119834 | 1.590738 | BMS-690514 | EGFR inhibitor, VEGFR inhibitor | EGFR, ERBB2, FLT3, KDR | null | null | COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1 | Phase 2 | true | ACH-000913 |
BRD-K76674262-001-03-3 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.368581 | 4.752062 | 0.541605 | 0.736342 | 0.173823 | 0.230263 | homoharringtonine | protein synthesis inhibitor | RPL3 | hematologic malignancy | chronic myeloid leukemia (CML) | COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC | Launched | true | ACH-000913 |
BRD-K76908866-001-07-6 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 1.198945 | 0.089251 | -0.047301 | 1 | 0.011741 | null | CP-724714 | EGFR inhibitor, protein tyrosine kinase inhibitor | ERBB2 | null | null | COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1 | Phase 2 | true | ACH-000913 |
BRD-K77625799-001-07-7 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.48378 | 0.58481 | 0.363042 | 0.842557 | 0.699526 | null | vandetanib | EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA | oncology | medullary thyroid cancer (MTC) | COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1 | Launched | true | ACH-000913 |
BRD-K78431006-001-15-1 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.963261 | -1.056601 | -0.075289 | 0.977007 | 0.270021 | null | crizotinib | ALK tyrosine kinase receptor inhibitor | ALK, MET | oncology | non-small cell lung cancer (NSCLC) | C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl | Launched | true | ACH-000913 |
BRD-K79254416-001-21-8 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 1.539343 | 1.437943 | 0.316109 | 1 | 1.915322 | null | decitabine | DNA methyltransferase inhibitor | DNMT1, DNMT3A | hematologic malignancy, hematology | myelodysplastic diseases (MDS), anemia, chronic myeloid leukemia (CML) | Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1 | Launched | true | ACH-000913 |
BRD-K81016934-001-02-0 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.858569 | 3.577421 | -0.045699 | 0.88886 | 0.004874 | null | INC-280 | c-Met inhibitor | MET | null | null | CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1 | Phase 2 | true | ACH-000913 |
BRD-K81418486-001-44-2 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.624251 | 0.115389 | 0.060295 | 0.838687 | 0.981152 | null | vorinostat | HDAC inhibitor | HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9 | hematologic malignancy | cutaneous T-cell lymphoma (CTCL) | ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1 | Launched | true | ACH-000913 |
BRD-K82135108-001-04-3 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.265767 | 2.382076 | 0.151972 | 0.490789 | 0.011936 | 0.01641 | elesclomol | oxidative stress inducer | HSPA1A | null | null | CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1 | Phase 3 | true | ACH-000913 |
BRD-K82746043-001-19-3 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.082171 | 0.722773 | 0.639257 | 0.782506 | 0.502444 | 0.644119 | navitoclax | BCL inhibitor | BCL2, BCL2L1, BCL2L2 | null | null | CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 | Phase 2 | true | ACH-000913 |
BRD-K82818427-001-04-8 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.810829 | -0.075127 | -0.147117 | 0.872062 | 1,575.168718 | null | batimastat | matrix metalloprotease inhibitor | ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8 | null | null | CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO | Phase 3 | true | ACH-000913 |
BRD-K83029223-001-01-3 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.263084 | 5.722328 | 0.708171 | 0.548912 | 0.001644 | 0.001873 | litronesib | kinesin-like spindle protein inhibitor | KIF11 | null | null | CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1 | Phase 2 | true | ACH-000913 |
BRD-K83988098-001-02-0 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.422929 | 8.770085 | 0.564068 | 0.880099 | 0.020771 | 0.025707 | alvespimycin | HSP inhibitor | HSP90AA1 | null | null | CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Phase 2 | true | ACH-000913 |
BRD-K85402309-043-01-9 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.104741 | 0.465089 | 0.282753 | 0.694885 | 0.550085 | 0.911867 | dovitinib | EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB | null | null | CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O | Phase 3 | true | ACH-000913 |
BRD-K85606544-001-09-1 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 33.469096 | 0.408606 | -0.03171 | 1 | 46,134,325.178118 | null | neratinib | EGFR inhibitor | EGFR, ERBB2, KDR | null | null | CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C | Phase 3 | true | ACH-000913 |
BRD-K86118762-001-01-8 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 1.00873 | -0.801477 | -0.332334 | 1 | 0.527245 | null | linsitinib | IGF-1 inhibitor | IGF1R, INSR, INSRR | null | null | C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 | Phase 3 | true | ACH-000913 |
BRD-K86972824-001-01-4 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 1.625104 | 2.371105 | 0.231677 | 1 | 2.416383 | null | oltipraz | nuclear factor erythroid derived, like (NRF2) activator | ANG | null | null | Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1 | Phase 3 | true | ACH-000913 |
BRD-K87737963-001-06-0 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 1.231584 | 1.203784 | -0.167837 | 1 | 0.443371 | null | cyt387 | null | JAK1, JAK2, JAK3 | null | null | O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1 | Phase 3 | true | ACH-000913 |
BRD-K87782578-001-01-4 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | -0.039771 | 0.513429 | 0.430502 | 0.718241 | 1.22742 | 1.057434 | AVL-292 | Bruton's tyrosine kinase (BTK) inhibitor | BTK, YES1 | null | null | COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1 | Phase 2 | true | ACH-000913 |
BRD-K87909389-003-03-4 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.347036 | 2.077423 | 0.779284 | 0.84456 | 0.347849 | 0.615175 | alvocidib | CDK inhibitor | CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM | null | null | CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl | Phase 2 | true | ACH-000913 |
BRD-K88510285-001-17-8 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.320131 | 3.577224 | 0.666906 | 0.720609 | 0.046399 | 0.061749 | bortezomib | NFkB pathway inhibitor, proteasome inhibitor | PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA | hematologic malignancy | multiple myeloma, mantle cell lymphoma (MCL) | CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O | Launched | true | ACH-000913 |
BRD-K89014967-001-04-3 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 1.176546 | 2.204382 | 0.063904 | 1 | 0.303621 | null | AS-703026 | MEK inhibitor | MAP2K1, MAP2K2 | null | null | OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F | Phase 2 | true | ACH-000913 |
BRD-K92441787-001-04-1 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 1.202368 | 3.237155 | 0.194846 | 1 | 0.458952 | null | bexarotene | retinoid receptor agonist | RXRA, RXRB, RXRG | hematologic malignancy | cutaneous T-cell lymphoma (CTCL) | Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C | Launched | true | ACH-000913 |
BRD-K92723993-001-17-4 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 1.010173 | -0.006701 | -0.033232 | 1 | 135,275.22256 | null | imatinib | Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor | ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET | hematologic malignancy, oncology | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST) | CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1 | Launched | true | ACH-000913 |
BRD-K95142244-001-01-5 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.517179 | 1.16217 | 0.589325 | 0.726316 | 0.040619 | null | talazoparib | PARP inhibitor | PARP2 | null | null | Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1 | Phase 3 | true | ACH-000913 |
BRD-K96123349-236-02-8 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 1.208938 | 0.111133 | -0.173312 | 1 | 0.04999 | null | brequinar | dihydroorotate dehydrogenase inhibitor | DHODH | null | null | Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F | Phase 2 | true | ACH-000913 |
BRD-K98572433-001-02-9 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.781374 | 0.600555 | -0.203157 | 0.874537 | 0.035017 | null | AZD8931 | EGFR inhibitor | EGFR, ERBB2, ERBB3 | null | null | CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC | Phase 2 | true | ACH-000913 |
BRD-K99113996-001-02-0 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.558207 | 0.675007 | 0.531162 | 0.752096 | 0.04113 | null | AZD2014 | mTOR inhibitor | MTOR | null | null | CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C | Phase 2 | true | ACH-000913 |
BRD-K99749624-001-07-0 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.928307 | -0.441063 | -0.022555 | 0.9563 | 0.304882 | null | linifanib | PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK | null | null | Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3[nH]nc(N)c23)c1 | Phase 3 | true | ACH-000913 |
BRD-M97302542-001-04-4 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.885781 | 2.893952 | 0.100047 | 0.926474 | 0.01936 | null | dichloroacetate | pyruvate dehydrogenase kinase inhibitor | PDK1 | null | null | [Na].OC(=O)C(Cl)Cl, [Na].OC(=O)C(Cl)Cl | Phase 3 | true | ACH-000913 |
BRD-A25234499-001-19-1 | ACH-000915 | IPC298_SKIN | MTS010 | 1 | 0.909641 | 0.21668 | 0.085879 | 0.958122 | 0.163143 | null | aminoglutethimide | glucocorticoid receptor antagonist | CYP11A1, CYP19A1 | endocrinology, oncology | Cushing's syndrome, breast cancer | CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1 | Launched | true | ACH-000915 |
BRD-A74914197-001-02-9 | ACH-000915 | IPC298_SKIN | MTS010 | 1 | 0.493741 | 4.454673 | 0.780987 | 0.756503 | 0.005869 | 0.015692 | pralatrexate | dihydrofolate reductase inhibitor | DHFR, TYMS | hematologic malignancy | peripheral T-cell lymphoma (PTCL) | Nc1nc(N)c2nc(CC(CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1 | Launched | true | ACH-000915 |
BRD-K02113016-001-19-6 | ACH-000915 | IPC298_SKIN | MTS010 | 1 | 0.930025 | -0.947358 | -0.051006 | 0.990047 | 0.001739 | null | olaparib | PARP inhibitor | PARP1, PARP2 | oncology | ovarian cancer | Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1, Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1 | Launched | true | ACH-000915 |
BRD-K02130563-001-11-4 | ACH-000915 | IPC298_SKIN | MTS010 | 1 | 0.107606 | 3.872417 | 0.884716 | 0.603649 | 0.134302 | 0.142976 | panobinostat | HDAC inhibitor | HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9 | hematologic malignancy | multiple myeloma | Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1 | Launched | true | ACH-000915 |
BRD-K03390685-001-01-7 | ACH-000915 | IPC298_SKIN | MTS010 | 1 | 0.094293 | 0.825776 | 0.89538 | 0.577909 | 0.10995 | 0.141614 | cobimetinib | MEK inhibitor | null | oncology | melanoma | OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1 | Launched | true | ACH-000915 |
BRD-K03406345-001-21-1 | ACH-000915 | IPC298_SKIN | MTS010 | 1 | 1.149265 | -0.320755 | -0.057837 | 1 | 0.000448 | null | azacitidine | DNA methyltransferase inhibitor | DNMT1, DNMT3A | hematologic malignancy, hematology | myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL) | Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000915 |
BRD-K03449891-001-08-6 | ACH-000915 | IPC298_SKIN | MTS010 | 1 | 1.205474 | 0.382446 | 0.002717 | 1 | 9.399056 | null | foretinib | VEGFR inhibitor | FLT1, FLT4, KDR, MET | null | null | COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1 | Phase 2 | true | ACH-000915 |
BRD-K03765900-001-01-9 | ACH-000915 | IPC298_SKIN | MTS010 | 1 | 2.07448 | 0.252922 | -0.223945 | 1 | 1,145.650151 | null | XL-647 | EGFR inhibitor, VEGFR inhibitor | EGFR, EPHB4, ERBB2, FLT4, KDR | null | null | COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1 | Phase 3 | true | ACH-000915 |
BRD-K05804044-001-18-5 | ACH-000915 | IPC298_SKIN | MTS010 | 1 | 0.074 | 0.76653 | 0.879982 | 0.641717 | 0.248954 | 0.30681 | AZ-628 | RAF inhibitor | BRAF, RAF1 | null | null | Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1 | Preclinical | true | ACH-000915 |
BRD-K06814349-304-02-7 | ACH-000915 | IPC298_SKIN | MTS010 | 1 | 0.895005 | -0.147513 | -0.035248 | 0.927311 | 23.762347 | null | fosbretabulin | tubulin polymerization inhibitor, VE-cadherin antagonist | CDH5 | null | null | COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O | Phase 3 | true | ACH-000915 |
BRD-K08109215-001-06-4 | ACH-000915 | IPC298_SKIN | MTS010 | 1 | 0.30655 | 0.53875 | 0.805958 | 0.762277 | 0.473874 | 2.761482 | I-BET-762 | bromodomain inhibitor | BRD2, BRD3, BRD4 | null | null | CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 | Phase 2 | true | ACH-000915 |
BRD-K08542803-001-02-3 | ACH-000915 | IPC298_SKIN | MTS010 | 1 | 0.051419 | 3.965822 | 0.874024 | 0.623935 | 0.21335 | 0.219269 | gambogic-acid | caspase activator | BCL2 | null | null | CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C | Phase 2 | true | ACH-000915 |
BRD-K08547377-001-04-4 | ACH-000915 | IPC298_SKIN | MTS010 | 1 | 0.496049 | 6.959603 | 0.57718 | 0.818133 | 0.301299 | 0.60403 | irinotecan | topoisomerase inhibitor | TOP1, TOP1MT | oncology | colorectal cancer | CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12 | Launched | true | ACH-000915 |
BRD-K08703257-001-13-9 | ACH-000915 | IPC298_SKIN | MTS010 | 1 | 1.052323 | -0.181709 | -0.029519 | 1 | 0.071229 | null | 3-amino-benzamide | PARP inhibitor | PARP1 | null | null | NC(=O)c1cccc(N)c1, NC(=O)c1cccc(N)c1 | Phase 2 | true | ACH-000915 |
BRD-K08799216-001-05-3 | ACH-000915 | IPC298_SKIN | MTS010 | 1 | -0.095956 | 6.419886 | 0.74245 | 0.97451 | 8.319154 | 8.09474 | pelitinib | EGFR inhibitor | EGFR | null | null | CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C | Phase 2 | true | ACH-000915 |
BRD-K09951645-001-11-8 | ACH-000915 | IPC298_SKIN | MTS010 | 1 | 0.736869 | 3.787881 | 0.550031 | 0.944387 | 1.28609 | null | dabrafenib | RAF inhibitor | BRAF, LIMK1, NEK11, RAF1, SIK1 | oncology | melanoma | CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F | Launched | true | ACH-000915 |
BRD-K11267252-001-05-1 | ACH-000915 | IPC298_SKIN | MTS010 | 1 | 0.834784 | -0.098295 | -0.021971 | 0.910006 | 0.500879 | null | alectinib | ALK tyrosine kinase receptor inhibitor | ALK, MET | oncology | non-small cell lung cancer (NSCLC) | CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1, CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1 | Launched | true | ACH-000915 |
BRD-K11630072-001-13-2 | ACH-000915 | IPC298_SKIN | MTS010 | 1 | 0.412836 | 2.505357 | 0.664638 | 0.923129 | 2.854698 | 5.732638 | carmofur | thymidylate synthase inhibitor | TYMS | oncology | breast cancer, colorectal cancer | CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O | Launched | true | ACH-000915 |
BRD-K12184916-001-19-6 | ACH-000915 | IPC298_SKIN | MTS010 | 1 | 0.770712 | 3.990103 | 0.399537 | 0.821642 | 0.005127 | null | NVP-BEZ235 | mTOR inhibitor, PI3K inhibitor | ATR, MTOR, PIK3CA, PIK3CD, PIK3CG | null | null | Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1, Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1 | Phase 2 | true | ACH-000915 |
BRD-K12343256-001-14-7 | ACH-000915 | IPC298_SKIN | MTS010 | 1 | 0.212562 | 2.243685 | 0.911186 | 0.41132 | 0.007053 | 0.009026 | trametinib | MEK inhibitor | MAP2K1, MAP2K2 | oncology | melanoma | CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O | Launched | true | ACH-000915 |
BRD-K13049116-001-04-0 | ACH-000915 | IPC298_SKIN | MTS010 | 1 | 0.821539 | -6.058951 | 0.417224 | 0.936241 | 0.019549 | null | BMS-754807 | IGF-1 inhibitor | AKT1, IGF1R | null | null | C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1 | Phase 2 | true | ACH-000915 |
BRD-K13390322-001-06-3 | ACH-000915 | IPC298_SKIN | MTS010 | 1 | 0.165866 | 2.934149 | 0.894906 | 0.802888 | 1.009765 | 1.158461 | AT-7519 | CDK inhibitor | CDK1, CDK2, CDK4, CDK5, CDK6, CDK9 | null | null | Clc1cccc(Cl)c1C(=O)Nc1c[nH]nc1C(=O)NC1CCNCC1 | Phase 2 | true | ACH-000915 |
BRD-K13514097-001-04-6 | ACH-000915 | IPC298_SKIN | MTS010 | 1 | 1.066559 | 1.672266 | 0.06768 | 1 | 0.031806 | null | everolimus | mTOR inhibitor | MTOR | oncology, neurology/psychiatry, genetics, urology | breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma | CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO | Launched | true | ACH-000915 |
BRD-K13662825-001-07-5 | ACH-000915 | IPC298_SKIN | MTS010 | 1 | 0.081266 | 2.69525 | 0.904431 | 0.530501 | 0.017573 | 0.018769 | dinaciclib | CDK inhibitor | CDK1, CDK2, CDK5, CDK9 | null | null | CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO | Phase 3 | true | ACH-000915 |
BRD-K14109347-001-03-4 | ACH-000915 | IPC298_SKIN | MTS010 | 1 | 0.299247 | 3.245773 | 0.880436 | 0.855544 | 1.353238 | 1.79256 | LY2603618 | CHK inhibitor | CHEK1 | null | null | Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1, Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1 | Phase 2 | true | ACH-000915 |
BRD-K15179879-001-03-2 | ACH-000915 | IPC298_SKIN | MTS010 | 1 | 0.110619 | 13.900494 | 0.921864 | 0.428404 | 0.019556 | 0.019911 | carfilzomib | proteasome inhibitor | PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9 | hematologic malignancy | multiple myeloma | CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1 | Launched | true | ACH-000915 |
BRD-K15600710-066-05-8 | ACH-000915 | IPC298_SKIN | MTS010 | 1 | 0.269726 | 5.870791 | 0.903913 | 0.719542 | 0.236281 | 0.26964 | obatoclax | BCL inhibitor | BCL2 | null | null | COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1, COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 | Phase 3 | true | ACH-000915 |
BRD-K16730910-001-10-7 | ACH-000915 | IPC298_SKIN | MTS010 | 1 | 0.347008 | 0.890421 | 0.606144 | 0.873644 | 1.929623 | 7.295679 | regorafenib | FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK | oncology | colorectal cancer, gastrointestinal stromal tumors (GIST) | CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1 | Launched | true | ACH-000915 |
BRD-K17555800-003-02-3 | ACH-000915 | IPC298_SKIN | MTS010 | 1 | 0.767557 | -0.526618 | 0.070032 | 0.955911 | 0.001602 | null | talmapimod | p38 MAPK inhibitor | MAPK11, MAPK14 | null | null | C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C | Phase 2 | true | ACH-000915 |
BRD-K17743125-001-08-4 | ACH-000915 | IPC298_SKIN | MTS010 | 1 | 0.076017 | 5.013344 | 0.82417 | 0.877833 | 2.7726 | 2.865337 | belinostat | HDAC inhibitor | HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9 | hematologic malignancy | peripheral T-cell lymphoma (PTCL) | ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1 | Launched | true | ACH-000915 |
BRD-K17894950-001-14-3 | ACH-000915 | IPC298_SKIN | MTS010 | 1 | 0.816491 | 0.764494 | 0.18304 | 0.877278 | 0.013632 | null | indirubin | CDK inhibitor, glycogen synthase kinase inhibitor | CDK1, CDK5, GSK3A | null | null | O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O | Phase 2/Phase 3 | true | ACH-000915 |
BRD-K18961567-001-01-1 | ACH-000915 | IPC298_SKIN | MTS010 | 1 | 0.722489 | 0.37043 | -0.012926 | 0.863997 | 0.089345 | null | LY2801653 | MET inhibitor | MET | null | null | Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1 | Phase 2 | true | ACH-000915 |
BRD-K19540840-001-09-4 | ACH-000915 | IPC298_SKIN | MTS010 | 1 | 0.84118 | -1.300392 | -0.044457 | 0.936859 | 0.028765 | null | saracatinib | src inhibitor | ABL1, LCK, SRC, YES1 | null | null | CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1 | Phase 2/Phase 3 | true | ACH-000915 |
BRD-K19687926-001-04-1 | ACH-000915 | IPC298_SKIN | MTS010 | 1 | 0.921971 | -1.118516 | -0.297054 | 0.98532 | 0.003345 | null | lapatinib | EGFR inhibitor | EGFR, ERBB2 | oncology | breast cancer | CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1 | Launched | true | ACH-000915 |
BRD-K19796430-001-05-6 | ACH-000915 | IPC298_SKIN | MTS010 | 1 | 1.010331 | 0.175728 | -0.01124 | 1 | 0.127113 | null | sonidegib | smoothened receptor antagonist | SMO | oncology | basal cell carcinoma (BCC) | C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1, C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1 | Launched | true | ACH-000915 |
BRD-K22064724-001-01-8 | ACH-000915 | IPC298_SKIN | MTS010 | 1 | 0.07226 | 4.637749 | 0.937093 | 0.627892 | 0.203955 | 0.210936 | napabucasin | STAT inhibitor | STAT3 | null | null | CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O, CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O | Phase 3 | true | ACH-000915 |
BRD-K22822991-001-02-3 | ACH-000915 | IPC298_SKIN | MTS010 | 1 | 1.011231 | -0.180827 | -0.006436 | 1 | 1.398174 | null | odanacatib | cathepsin inhibitor | CTSK | null | null | CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N | Phase 3 | true | ACH-000915 |
BRD-K23228615-001-02-8 | ACH-000915 | IPC298_SKIN | MTS010 | 1 | 0.613637 | 1.424729 | 0.334614 | 0.963183 | 4.936165 | null | GDC-0980 | mTOR inhibitor, PI3K inhibitor | FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK | null | null | C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1 | Phase 2 | true | ACH-000915 |
BRD-K23984367-001-07-5 | ACH-000915 | IPC298_SKIN | MTS010 | 1 | 0.376854 | 3.362539 | 0.567894 | 0.91736 | 2.771911 | 4.204927 | sorafenib | FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET | oncology | renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC) | CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1 | Launched | true | ACH-000915 |
BRD-K26026438-001-01-0 | ACH-000915 | IPC298_SKIN | MTS010 | 1 | 0.954897 | -1.799707 | 0.047823 | 0.976443 | 0.096967 | null | tucatinib | EGFR inhibitor | ERBB2 | null | null | Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1 | Phase 2 | true | ACH-000915 |
BRD-K26657438-001-15-2 | ACH-000915 | IPC298_SKIN | MTS010 | 1 | 0.913718 | 0.596608 | 0.001781 | 0.918929 | 0.000143 | null | imiquimod | interferon inducer, toll-like receptor agonist | TLR7, TLR8 | dermatology, infectious disease, oncology | actinic keratosis (AK), genital warts, basal cell carcinoma (BCC) | CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12 | Launched | true | ACH-000915 |
BRD-K28822270-001-03-7 | ACH-000915 | IPC298_SKIN | MTS010 | 1 | 0.289284 | 1.861842 | 0.713648 | 0.853279 | 1.429995 | 2.274543 | resminostat | HDAC inhibitor | HDAC1, HDAC3, HDAC6, HDAC8 | null | null | CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO | Phase 2 | true | ACH-000915 |
BRD-K29905972-001-06-3 | ACH-000915 | IPC298_SKIN | MTS010 | 1 | 0.849328 | 2.842434 | 0.284507 | 0.916571 | 0.046373 | null | axitinib | PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1, FLT1, FLT4, KDR, PLK4 | oncology | renal cell carcinoma (RCC) | CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1 | Launched | true | ACH-000915 |
BRD-K30577245-001-05-0 | ACH-000915 | IPC298_SKIN | MTS010 | 1 | 0.711933 | 3.545222 | 0.37491 | 0.843569 | 0.003214 | null | docetaxel | tubulin polymerization inhibitor | BCL2, MAP2, MAP4, MAPT, NR1I2, TUBB, TUBB1 | oncology | breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC) | CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C | Launched | true | ACH-000915 |
BRD-K31698212-001-02-9 | ACH-000915 | IPC298_SKIN | MTS010 | 1 | 1.378767 | 1.506525 | 0.373335 | 1 | 1.383445 | null | icotinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1 | Launched | true | ACH-000915 |
BRD-K31928526-001-02-1 | ACH-000915 | IPC298_SKIN | MTS010 | 1 | 0.970134 | 0.240682 | -0.05515 | 0.978845 | 0.001334 | null | barasertib | Aurora kinase inhibitor | AURKA, AURKB | null | null | CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(O)(O)=O | Phase 2/Phase 3 | true | ACH-000915 |
BRD-K33379087-001-07-5 | ACH-000915 | IPC298_SKIN | MTS010 | 1 | 0.709144 | 0.26356 | 0.20399 | 0.87892 | 0.333309 | null | tivantinib | tyrosine kinase inhibitor | MET | null | null | O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23 | Phase 3 | true | ACH-000915 |
BRD-K33610132-001-02-9 | ACH-000915 | IPC298_SKIN | MTS010 | 1 | 0.927905 | -0.267785 | 0.00996 | 0.97626 | 0.00387 | null | rociletinib | EGFR inhibitor | EGFR | null | null | COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O | Phase 3 | true | ACH-000915 |
BRD-K33622447-066-01-9 | ACH-000915 | IPC298_SKIN | MTS010 | 1 | 0.678057 | 3.62857 | 0.440663 | 0.867089 | 0.181973 | null | abemaciclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1 | Launched | true | ACH-000915 |
BRD-K35520305-001-16-9 | ACH-000915 | IPC298_SKIN | MTS010 | 1 | 0.763483 | 0.252205 | 0.162425 | 0.868786 | 0.02937 | null | dacarbazine | DNA alkylating agent | PGD, POLA2 | oncology, hematologic malignancy | melanoma, Hodgkin's lymphoma | CN(C)\N=N\c1[nH]cnc1C(N)=O, CN(C)\N=N\c1[nH]cnc1C(N)=O | Launched | true | ACH-000915 |
BRD-K36627727-001-05-4 | ACH-000915 | IPC298_SKIN | MTS010 | 1 | 0.853402 | 1.055089 | 0.173481 | 0.919663 | 0.04873 | null | tamibarotene | retinoid receptor agonist | RARA, RARB | hematologic malignancy | acute promyelocytic leukemia (APL) | CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12 | Launched | true | ACH-000915 |
BRD-K36788280-001-01-2 | ACH-000915 | IPC298_SKIN | MTS010 | 1 | 0.871206 | 0.171635 | -0.008347 | 0.913883 | 0.001044 | null | ribociclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1 | Launched | true | ACH-000915 |
BRD-K37379014-001-02-0 | ACH-000915 | IPC298_SKIN | MTS010 | 1 | 0.795768 | -0.046331 | -0.05747 | 0.889709 | 0.039471 | null | filanesib | kinesin inhibitor, kinesin-like spindle protein inhibitor | KIF11 | null | null | CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F | Phase 3 | true | ACH-000915 |
BRD-K38332599-001-01-3 | ACH-000915 | IPC298_SKIN | MTS010 | 1 | 0.941455 | 0.082816 | -0.053453 | 0.983909 | 11,060.551039 | null | uprosertib | AKT inhibitor | AKT1, AKT2, AKT3 | null | null | Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1 | Phase 2 | true | ACH-000915 |
BRD-K38527262-300-01-0 | ACH-000915 | IPC298_SKIN | MTS010 | 1 | 0.166267 | 4.196718 | 0.806144 | 0.80399 | 0.940196 | 1.03527 | atiprimod | JAK inhibitor, STAT inhibitor | JAK2, STAT3 | null | null | CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1 | Phase 2 | true | ACH-000915 |
BRD-K38852836-001-02-1 | ACH-000915 | IPC298_SKIN | MTS010 | 1 | 0.497776 | 3.369321 | 0.796811 | 0.774946 | 0.032353 | 0.161404 | ganetespib | HSP inhibitor | HSP90AA1 | null | null | CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O | Phase 3 | true | ACH-000915 |
BRD-K39974922-001-04-3 | ACH-000915 | IPC298_SKIN | MTS010 | 1 | 0.885493 | -2.078542 | 0.031255 | 0.903287 | 2.261205 | null | lenvatinib | FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | FLT4, KDR | oncology | thyroid cancer | COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O | Launched | true | ACH-000915 |
BRD-K41859756-001-06-8 | ACH-000915 | IPC298_SKIN | MTS010 | 1 | 0.577514 | 3.634481 | 0.78407 | 0.757429 | 0.009526 | null | NVP-AUY922 | HSP inhibitor | HSP90AA1, HSP90AB1 | null | null | CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O | Phase 2 | true | ACH-000915 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.